Abstract

Euglycemic diabetic ketoacidosis (euDKA) is an emergency situation associated with diabetes which has recently drawn clinicians’ attention due to its association with the administration of the novel class of antidiabetic’s sodium-glucose cotransporter 2 (SGLT2) inhibitors. The use of SGLT-2 inhibitors is on the rise, thanks to their primary and secondary cardioprotective effects. In the context of SGLT-2 inhibitor administration, major operation may precipitate euDKA. One such example is pancreatoduodenectomy, which is notorious for a multitude of associated complications, nevertheless has gained popularity over recent years because of its therapeutic impact on periampullary and pancreatic head malignancies. Familiarization with the technique has expanded its implication to patient groups who would otherwise be considered as “high risk”. The surgeon and any related clinician must be aware of the rising complication of euDKA following pancreatoduodenectomy